Whitehead William E, Palsson Olafur S, Levy Rona L, Feld Andrew D, VonKorff Michael, Turner Marsha
Division of Gastroenterology and Hepatology and Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7080, USA.
Am J Gastroenterol. 2006 May;101(5):1057-65. doi: 10.1111/j.1572-0241.2006.00535.x.
Treatment trials for irritable bowel syndrome (IBS) usually define a responder as a patient who reports satisfactory relief or adequate relief of symptoms at the end of the trial. However, these measures have not been adequately validated.
(1) Compare a binary satisfactory relief measure to alternative ways of defining a treatment responder. (2) Determine whether baseline IBS symptom severity or psychological distress influence the sensitivity of these outcome measures.
A total of 350 patients (81% females, average age 50 yr) who had a medical diagnosis of IBS and satisfied Rome II criteria, were recruited from Group Health Cooperative of Puget Sound. At baseline the Irritable Bowel Severity Scale (IBSS) was used to assess symptom severity and to classify patients as mild, moderate, or severe. Psychological distress and IBS-specific quality of life (IBS-QOL) were also assessed. After 6 months treatment with standard medical care, IBSS and IBS-QOL were reassessed, and patients were asked whether they had experienced satisfactory relief and whether they were somewhat or markedly better.
Initial severity of IBS significantly affected the proportion who reported satisfactory relief (mild, 72%; moderate, 53%; severe, 44%) and the proportion who were somewhat or markedly better (mild, 62%; moderate, 44%; severe, 38%), but did not affect the proportion with a 50% reduction in symptoms (mild, 26%; moderate, 25%; severe, 23%). Although mild patients were the most likely to report satisfactory relief, they showed no average decrease in symptom severity or improvement in IBS-QOL. Conversely, severe patients, who were the least likely to report satisfactory relief, had the largest reductions in IBS symptom severity and the largest improvements in IBS-QOL. Psychological distress had no significant effect on the responder rate after adjusting for IBS symptom severity.
These data from a descriptive study suggest that satisfactory relief is confounded with initial IBS symptom severity and is poorly correlated with the amount of symptom improvement. Confirmation of these findings in a clinical trial is needed.
肠易激综合征(IBS)的治疗试验通常将治疗反应者定义为在试验结束时报告症状得到满意缓解或充分缓解的患者。然而,这些衡量标准尚未得到充分验证。
(1)将二元满意缓解衡量标准与定义治疗反应者的其他方法进行比较。(2)确定基线IBS症状严重程度或心理困扰是否会影响这些结局衡量标准的敏感性。
从普吉特海湾健康合作组织招募了350例经医学诊断为IBS且符合罗马II标准的患者(81%为女性,平均年龄50岁)。在基线时,使用肠易激严重程度量表(IBSS)评估症状严重程度,并将患者分为轻度、中度或重度。还评估了心理困扰和IBS特异性生活质量(IBS-QOL)。经过6个月的标准医疗护理治疗后,重新评估IBSS和IBS-QOL,并询问患者是否经历了满意的缓解,以及他们是否有所好转或明显好转。
IBS的初始严重程度显著影响报告满意缓解的比例(轻度,72%;中度,53%;重度,44%)以及有所好转或明显好转的比例(轻度,62%;中度,44%;重度,38%),但不影响症状减轻50%的比例(轻度,26%;中度,25%;重度,23%)。尽管轻度患者最有可能报告满意缓解,但他们的症状严重程度并未出现平均下降,IBS-QOL也未得到改善。相反,重度患者最不可能报告满意缓解,但IBS症状严重程度下降幅度最大,IBS-QOL改善幅度最大。在调整IBS症状严重程度后,心理困扰对治疗反应率没有显著影响。
这项描述性研究的数据表明,满意缓解与IBS初始症状严重程度混淆,且与症状改善程度相关性较差。需要在临床试验中对这些发现进行验证。